Unlocking the Power of DNA Exonucleases and Endonucleases in Immunity

March 02, 2025 02:28 PM AEDT | By EIN Presswire
 Unlocking the Power of DNA Exonucleases and Endonucleases in Immunity
Image source: EIN Presswire

SHANNON, CLARE, IRELAND, March 1, 2025 /EINPresswire.com/ -- A recent review highlights the critical role of DNA exonucleases and endonucleases in immune response and disease management, shedding new light on their potential applications in genomic stability, autoimmune disorders, and cancer treatment.

DNA exonucleases and endonucleases are essential in maintaining genome integrity, executing precise cleavage of damaged or foreign DNA to initiate immune responses. These nucleases play a pivotal role in activating key innate immune pathways, such as the cGAS-STING pathway, which enables the body to mount an effective anti-viral and anti-tumor response.

The analysis explores the dual-edged nature of genomic instability, revealing how mutations in these nucleases contribute to various autoimmune diseases, including rheumatoid arthritis and Aicardi-Goutières syndrome. Conversely, targeting exonuclease and endonuclease activity could be leveraged to disrupt the genomic integrity of cancer cells, increasing their susceptibility to immunotherapy and radiation treatments.

MRE11, a nuclease with dual exonuclease and endonuclease activity, is crucial for DNA damage repair and modulating the immune response. It also plays a role in T-cell lifespan regulation, making it a potential target for autoimmune therapies. EXO1, known for its role in mismatch repair (MMR), influences the immune response by enhancing checkpoint therapies in specific cancer types, particularly those with microsatellite instability (MSI). TREX1, a cytoplasmic exonuclease, prevents dsDNA accumulation, thereby reducing autoimmunity risks while also acting as a key regulator of tumor immunogenicity in radiotherapy. FEN1 and MUS81-EME1, essential for DNA metabolism and repair, are linked to tumor proliferation and could be targeted to enhance immunotherapy efficacy.

The findings highlight the potential of nuclease-based therapeutic interventions for both immune disorders and cancer. Understanding how these enzymes regulate DNA integrity and immune signaling offers promising avenues for future exploration, with significant implications for personalized medicine and immunotherapy strategies.

This review opens the door to novel therapeutic targets, emphasizing the importance of a balanced approach in leveraging nuclease activity to combat disease progression while preserving genomic stability.

Funding Information:
Beijing Xisike Clinical Oncology Research Foundation Y-HR2020MS-0156
National Natural Science Foundation of China 82273130

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus CiteScore: 7.3
Impact Factor: 6.9

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/

All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases ).

Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: [email protected]

X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )

# # # # # #

Reference
Mingjun Lu, Jinghong Wu, Qing Gao, Renjing Jin, Changming An, Teng Ma, To cleave or not and how? The DNA exonucleases and endonucleases in immunity, Genes & Diseases, Volume 12, Issue 2, 2025, 101219, https://doi.org/10.1016/j.gendis.2024.101219

Genes & Diseases Editorial Office
Genes & Diseases
+86 23 6571 4691
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.